Medtronic stock holds steady as FY 2027 dividend and earnings support outlook

Medtronic plc (ISIN IE00BTN1Y115) stock is trading in the low-$90s in late August 2026 as investors digest fresh fiscal 2027 earnings guidance, a newly approved cash dividend for the second quarter of fiscal year 2027, and solid revenue growth in the most recent quarter reported on June 3, 2026.

Dividend decision underpins income profile

On August 20, 2026, the board of directors approved a cash dividend for the second quarter of fiscal year 2027 of $0.72 per ordinary share, reinforcing Medtronic's profile as a long-term income name. The payment is scheduled for October 16, 2026, to shareholders of record at the close of business on September 25, 2026, giving investors clear visibility on near-term cash returns. The company highlights that this declaration is consistent with the dividend increase announced in June 2026, and notes its inclusion in the S&P 500 Dividend Aristocrats index after increasing its annual dividend for 49 consecutive years. For yield-oriented shareholders, a $0.72 quarterly dividend translates into $2.88 on an annualized basis, aligning with a dividend yield of roughly 3.1% when measured against a share price in the low-$90s range reported in recent market data.

The dividend announcement signals management's confidence in cash generation and balance sheet flexibility through fiscal 2027. By committing to a payout level that maintains its long streak of dividend increases, Medtronic is effectively prioritizing capital returns alongside ongoing investment in devices and health technology. The ex-dividend date tied to this payout falls on September 25, 2026, giving current and prospective investors a discrete calendar marker for income positioning ahead of the October payment.

Latest quarter shows mid-single-digit EPS and near-10 percent revenue growth

In its most recent quarterly earnings release on June 3, 2026, Medtronic reported earnings per share of $1.55, modestly ahead of the $1.54 consensus estimate, demonstrating operational stability even as the company invests in new technologies. Quarterly revenue reached $9.81 billion, outpacing analyst expectations of $9.62 billion and indicating demand momentum across its portfolio of cardiac, surgical, restorative, and diabetes therapies. The reported 9.9% year-over-year increase in revenue offers a clear comparison with the same quarter in the prior fiscal year, when the company generated roughly $8.93 billion in sales.

Profitability metrics in that June 2026 quarter underline the earnings quality behind the headline growth. Medtronic posted a net margin of 13.20% and a return on equity of 14.51%, reflecting disciplined cost control and productive use of shareholder capital. By contrast, the same quarter in the previous year delivered earnings per share of $1.62 on lower revenue, suggesting that the current period's slightly lower EPS has been supported by higher topline expansion. Sell-side analysts collectively forecast that Medtronic will deliver 5.94 earnings per share for the current fiscal year, while management has set guidance for fiscal 2027 EPS in a range between 5.90 and 6.00, offering investors a quantified view of medium-term profit expectations.

Balance sheet indicators help frame that earnings power. Recent market data shows Medtronic with a market capitalization of roughly $119.60 billion at a share price around $93.44, implying a price-to-earnings ratio of 25.05 on trailing earnings and a price/earnings-to-growth (P/E/G) ratio of 2.47. Liquidity metrics include a quick ratio of 1.62 and a current ratio of 2.13, while leverage remains moderate at a debt-to-equity ratio of 0.52. Together, these figures suggest the company retains capacity to fund ongoing R&D, acquisitions, and shareholder returns without stretching its balance sheet.

Institutional flows and valuation context

Institutional interest continues to support Medtronic's shareholder base. A filing released in August 2026 shows Alpine Woods Capital Investors LLC taking a new position in Medtronic during the second quarter, purchasing 68,491 shares valued at $5,358,000. With Medtronic representing 1.2% of that firm's investment portfolio and ranking as its 27th largest holding, the move underlines the stock's appeal as a core healthcare technology exposure. Across the shareholder register, financial filings indicate that institutional investors collectively own more than 80% of Medtronic's outstanding shares, providing liquidity and often stabilizing trading behavior through diversified long-horizon capital.

Brokerage research compiled in recent weeks points to a favorable, though not exuberant, view from the analyst community. Eighteen analysts currently rate Medtronic shares as a Buy and nine carry a Hold recommendation, producing a consensus rating identified as Moderate Buy. The average published price target stands at $98.83, which is roughly 5.8% above the recent share level around $93.44, suggesting that Wall Street sees scope for modest upside as earnings and cash flows develop along guided trajectories. For investors, that spread between the latest trading price and the average target adds a quantifiable valuation cushion, although it also reflects relatively measured expectations compared to higher-growth medtech peers.

From a trading standpoint, Medtronic shares have recently opened at $93.44 on the New York Stock Exchange, within a twelve-month range that spans from a low of $73.31 to a high of $106.33. This places the current quote closer to the upper half of the 52-week band, indicating that the stock has already recovered from its lower levels earlier in the year but remains below its recent peak. Technical markers show a fifty-day simple moving average of $84.39 and a 200-day simple moving average of $86.06, so the current price trades above both averages. That positioning can be interpreted as a constructive signal for momentum-focused investors, who often look for shares trading above medium- and long-term averages as evidence of persistent buying interest.

Medtronic's portfolio and a flagship diabetes technology

Medtronic describes itself as a leading global healthcare technology company focused on alleviating pain, restoring health, and extending life across more than 70 health conditions. It operates in multiple clinical segments, including cardiac rhythm and heart failure therapies, advanced surgical and minimally invasive technologies, restorative therapies for spine and neurological conditions, and diabetes management. With a workforce of more than 95,000 employees across 150 countries, the company leverages scale to distribute devices and integrated solutions into hospitals, clinics, and health systems worldwide, while maintaining legal headquarters in Galway, Ireland and principal operational offices in the United States.

One representative product area that illustrates Medtronic's strategy is its diabetes technology portfolio, which includes insulin delivery systems and continuous glucose monitoring solutions designed to give patients more precise and automated control over glycemic levels. These systems typically combine wearable insulin pumps with sensors and software algorithms that adjust dosing based on real-time glucose measurements. For people living with type 1 diabetes and insulin-dependent type 2 diabetes, such integrated devices aim to reduce episodes of hyperglycemia and hypoglycemia, improve overall time-in-range metrics, and lessen the day-to-day burden of manual insulin management. In markets where reimbursement frameworks support advanced diabetes technology, this segment can contribute recurring revenue streams through device sales, disposables, and service contracts.

Market view as of the latest trading session

As of the most recent completed trading session in late August 2026, Medtronic stock trading around $93.44 on the New York Stock Exchange reflects a blend of steady earnings delivery, a secure and rising dividend, and moderate growth expectations embedded in consensus forecasts. With a 52-week range between $73.31 and $106.33 and the current price above both the fifty-day and 200-day moving averages, investors see shares as stabilizing in a zone that balances defensive cash-flow characteristics with exposure to long-term growth in medical devices and health technology. For now, the combination of an annualized $2.88 dividend aligned with a yield near 3.1% and guidance pointing to fiscal 2027 EPS between 5.90 and 6.00 underpins Medtronic's positioning as a core holding in diversified healthcare portfolios.